On December 24, the Daily Economic News hosted the 10th China Listed Companies Summit Week of 2021. As an annual honorary ceremony in the Chinese capital market, it released the award ceremony of "2021 China Listed Companies Reputation Ranking", adding a most deserved honour to more than 100 listed companies that are serious about their primary business and stick to their values.

With years of inputs in biomedicine and excellent leadership, Mr K.C. Kun, the founder and president of Hybribio, was awarded the title of "the Best CEO of Listed Company", and Hybribio was elected as "Most Promising Listed Company in Biomedicine".

The organizer's award speech for Mr Kun was: "a 70-year-old literati scholar who has great patriotic sentiment; caring for women and children, guarding human health! 20 years of Hybribio’s development, with cooperation and innovation; conscientious quality, scientific management", and Hybribio was elected as the "Most Promising Listed Company in Biomedicine". Mr Kun and Hybribio Group were highly affirmed and praised for their efforts in guarding the health of our country.

On Mr Kun's birthday, the two awards received were the most meaningful birthday gifts for him. Mr Kun, the founder and president of Hybribio, has proposed "the pursuit of the country is the pursuit of Hybribio" since the beginning of Hybribio's establishment. It forms Hybribio's development strategy which is to closely follow the national public health and disease prevention policies and devote to the research and development of products that can genuinely solve the public health problems. Hybribio's ambition is to guard the health and safety of the nation's life. Mr Kun's " patriotic sentiment" for the country and the people lays in his dedication to the biotechnology industry, and Hybribio’s mission has remained unchanged over the years.

With nearly 20 years of development, Mr Kun has led his research team to overcome difficulties and break through the technical barrier. They successfully developed HPV test kits and spared no effort to promote advanced HPV typing test technology for mass screening of cervical cancer. To protect maternal and child health, Mr Kun keeps expanding the product line and developing a series of testing products covering birth defects, hereditary diseases, tumours, infectious diseases, etc.

To date, Hybribio has conducted cervical cancer screening for women in Shanghai, Hainan, Tibet, Fujian, Shanxi, Qinghai, Hebei, Guangdong and other cities and villages, providing HPV screening services for over 40 million women in total. Under the forward-looking strategy, Hybribio has implemented the development strategy of "Three Hybribio", "Nucleic Acid 99, 999", and "Hybribio B53". It gives full play to Hybribio's advantages in product research and development and production capacity, providing excellent services on multiple technology platforms for national medical institutions at all levels to benefit people with science and technology in a better way.

Hybribio has performed exceptionally well in the in vitro diagnostic industry and biotechnology field with conscientious quality and scientific management and has made significant progress in various business indexes. In the prevention and control of the novel coronavirus epidemic in the past two years, Hybribio's "iron army" has been in the front and dared to take charge. Hybribio becomes a vital force in the nationwide fight against the novel coronavirus epidemic. At present, 27 medical laboratories nationwide have been designated by the Health and Welfare Commission as nucleic acid testing institutions. They are fully engaged in the battle against the epidemic, participating in the universal screening tasks in more than 30 cities like Wuhan, Hong Kong, Guangzhou, Ruili, Nanjing and Xiamen.

Recently, the epidemic situation in Xian was severe, so Hybribio urgently deployed its elite forces from all over China and sent nearly 200 testing elites to form an anti-epidemic team to carry out large-scale screening work in Xian at night. Hybribio brought two mobile PCR laboratories and equipped over 100 nucleic acid testing instruments, with a daily testing capacity of over 100,000 tubes and 1 million samples. We have completed the first phase of nucleic acid testing and are still fighting bravely on the front line to contribute to the prevention and control of the epidemic in Xian.

This time, with double happiness, Hybribio was awarded two major honours in the 2021 China Listed Companies Reputation Rankings, which show that the investors and the capital market fully recognize the promising future of Hybribio Group and the high-quality management of the senior management team. As a leading biotechnology enterprise in China, Hybribio Group will continue to adhere to high-quality, independent innovation and increase its investment in R&D in molecular diagnostics. Hybribio will develop around the trinity of molecular diagnostic products, third-party medical testing services and medical health management, promote precision medical services for the benefit of the public, and return to the capital market and investors with excellent business performance and outstanding results.